Contraceptive developer Contraline raised $92.5 million to advance two male birth control candidates, including a once-daily topical gel and an implantable option. The financing underscores investor appetite for non-hormonal and reversible contraception platforms that can broaden options beyond female-focused pipelines. While specific clinical endpoints and timelines were not detailed in the funding announcement, the company’s two-program structure suggests parallel optimization of adherence and pharmacology across delivery modalities. The round also points to continued scale-up efforts to take male contraception into larger efficacy and safety studies. If successful, Contraline’s approach could address a major unmet need in population-level contraception access and expand the competitive field beyond established fertility-control paradigms.